There should be several corrections in "Use of Enoxaparin, a Low-Molecular-Weight Heparin, and Unfractionated Heparin for the Prevention of Deep Venous Thrombosis after Elective Hip Replacement. A Clinical Trial Comparing Efficacy and Safety" (76-A:3-14, Jan. 1994), by Colwell et al. The effect of these changes is to show more clearly that enoxaparin was significantly more effective than unfractionated heparin in the prevention of deep venous thrombosis in the evaluable patients (p=0.03).

On page 3, right-hand column, paragraph 3, line 6, which presently reads, "...(twenty-one [15 per cent] of 145 patients) (p=0.10)," should read, "...(twenty-one [15 per cent] of 142 patients) (p=0.03)." The following two lines, which presently read, "however, this difference was not significant because of the small number of patients included in this analysis," should be deleted.

On page 7, right-hand column, line 1, which presently reads, "that received heparin was not significant (p=0.52)..." should read, "that received hepanin was significant (p=0.03)..."

On page 12, right-hand column, paragraph 3, lines 14 through 24, which presently begin with the line, "Neither the evaluable-patient analysis nor the analysis of..." and end with the line, "two treatment groups. No occurrences of clinically..." should be deleted. In their place, the following lines should be inserted: "The evaluable-patient analysis revealed a significant difference in the rate of deep venous thrombosis between the group that received thirty milligrams of enoxaparin every twelve hours (eight [6 per cent] of 136 patients) and the group that received heparin (twenty-one [15 per cent] of 142 patients) (p=0.03). No occurrences of clinically..."